Norepinephrine and concentric hypertrophy in patients with end-stage renal disease

Hypertension

Volumn 40, Issue 1, 2002, Pages 41-46

  Zoccali, Carmine ^a   Mallamaci, Francesca ^a   Tripepi, Giovanni ^a   Parlongo, Saverio ^a   Cutrupi, Sebastiano ^a   Benedetto, Francesco Antonio ^b   Cataliotti, Alessandro ^c   Malatino, Lorenzo Salvatore ^c  

^a CNR   (Italy)

^b Morelli Hospital   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

Author keywords

Cardiovascular risk; Dialysis; Left ventricular hypertrophy; Norepinephrine; Renal failure; Sympathetic activity; Uremia

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BICARBONATE; C REACTIVE PROTEIN; CALCIUM; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN; HOMOCYSTEINE; LIPID; NORADRENALIN; PHOSPHATE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL MODEL; SYMPATHETIC TONE; UREMIA;

ADULT; AGED; COHORT STUDIES; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NOREPINEPHRINE; REGRESSION ANALYSIS; RENAL DIALYSIS;

EID: 0036311224     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000022063.50739.60     Document Type: Article

References (38)

1. Impact of left ventricular hypertrophy on survival in end-stage renal disease
2. The prognostic importance of left ventricular geometry in uremic cardiomyopathy
3. Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis
4. Left ventricular hypertrophy in the renal patient
5. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure
6. Sympathetic overactivity in patients with chronic renal failure
7. The kidney and the neurogenic control of blood pressure in renal disease
8. Sympathetic overactivity as a cause of hypertension in chronic renal failure
9. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end stage renal disease
10. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage
11. High-performance liquid chromatographic method for measuring total plasma homocysteine levels
12. Plasma metanephrine in the diagnosis of pheochromocytoma
13. Prediction of left ventricular geometry by clinic, pre-dialysis and 24-h ambulatory BP monitoring in hemodialysis patients
14. Left ventricular mass and body size in normotensive children and adults: Assessment of allometric relations and impact of overweight
15. The prognostic impact of the indexations of left ventricular mass in dialysis patients
16. Ageing induces left ventricular concentric remodeling in normotensive subjects
17. Plasma noradrenaline levels in regular haemodialysis patients
18. Red blood cell catechol-o-methyl transferase, plasma catecholamines and renin in renal failure
19. Competitive effects of hypokalemia and volume depletion on plasma renin activity, aldosterone and catecholamine concentrations in hemodialysis patients
20. Catecholamines in peripheral venous plasma in patients on chronic hemodialysis
21. Sympathetic nervous system hyperactivity in maintenance hemodialysis patients
22. Plasma noradrenaline and blood pressure in uremia
23. Norepinephrine-related mechanism in hypertension accompanying renal failure
24. Plasma norepinephrine, epinephrine, and dopamine levels in end-stage renal disease: Effect of hemodialysis
25. Plasma free, sulfo- and glucuro-conjugated catecholamines in uremic patients
26. How to assess sympathetic activity in humans
27. 1 adrenergic response
28. Cardiac and arterial interactions in end-stage renal disease
29. Sympathetic tone restrains arterial distensibility of healthy and atherosclerotic subjects
30. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease
31. Postischemic vasodilation, endothelial activation, and cardiovascular remodeling in end-stage renal disease
32. Hypertensive left ventricular hypertrophy: Relation to peripheral sympathetic drive
33. Sex-specific determinants of increased left ventricular mass in the Tecumseh blood pressure study
34. Left ventricular mass is linked to cardiac noradrenaline in normotensive and hypertensive patients
35. Increased cardiac sympathetic activity and insulin-like growth factor-I formation are associated with physiological hypertrophy in athletes
36. Enhanced cardiac clearance of iodine-123-MIBG in chronic renal failure
37. Two properties of multiple regression analysis and regression to the mean (and regression from the mean)
38. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here?